Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 3
1995 2
1997 7
1998 2
1999 4
2000 7
2001 1
2002 2
2003 6
2004 4
2005 1
2006 2
2007 1
2008 2
2009 1
2010 2
2011 1
2012 1
2013 2
2016 2
2018 1
2019 2
2020 3
2021 2
2022 1
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Drug-induced blaschkitis.
Brinkmeier T, Herbst RA, Schaller J, Kuegler K, Pirker C, Beiteke U, Grosshans E, Frosch PJ. Brinkmeier T, et al. Among authors: herbst ra. Acta Derm Venereol. 2004;84(4):314-5. doi: 10.1080/00015550410025282. Acta Derm Venereol. 2004. PMID: 15339081 Free article. No abstract available.
[Histological diagnosis of onychomycosis].
Herbst RA, Brinkmeier T, Frosch PJ. Herbst RA, et al. J Dtsch Dermatol Ges. 2003 Mar;1(3):177-80. doi: 10.1046/j.1610-0387.2003.02033.x. J Dtsch Dermatol Ges. 2003. PMID: 16285492 German.
[Metastasized occult melanomas?].
Kellner I, Herbst RA. Kellner I, et al. Among authors: herbst ra. Hautarzt. 2016 Mar;67(3):242-3. doi: 10.1007/s00105-015-3725-7. Hautarzt. 2016. PMID: 26604193 German.
Mutation and expression of TP53 in malignant melanomas.
Weiss J, Heine M, Arden KC, Körner B, Pilch H, Herbst RA, Jung EG. Weiss J, et al. Among authors: herbst ra. Recent Results Cancer Res. 1995;139:137-54. doi: 10.1007/978-3-642-78771-3_10. Recent Results Cancer Res. 1995. PMID: 7597286 Review.
Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.
Livingstone E, Gogas HJ, Kandolf L, Meier F, Eigentler TK, Ziemer M, Terheyden P, Gesierich A, Herbst RA, Kähler KC, Ziogas DC, Mijušković Ž, Garzarolli M, Garbe C, Roesch A, Ugurel S, Gutzmer R, Gaudy-Marqueste C, Kiecker F, Utikal J, Hartmann M, Miethe S, Eckhardt S, Zimmer L, Schadendorf D. Livingstone E, et al. Among authors: herbst ra. ESMO Open. 2025 May;10(5):105053. doi: 10.1016/j.esmoop.2025.105053. Epub 2025 May 8. ESMO Open. 2025. PMID: 40345056 Free PMC article. Clinical Trial.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group. Livingstone E, et al. Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099927 Clinical Trial.
64 results